spacer
home > epc > autumn 2003 > industry trends in the development and provision of 21 cfr part 11-compatible equipment
PUBLICATIONS
European Pharmaceutical Contractor

Industry Trends in the Development and Provision of 21 CFR Part 11-Compatible Equipment

Background

The FDA's 21 CFR Part 11 has been in effect since August 1997. Part 11 establishes the standards for ensuring electronic records and electronic signatures are as trustworthy and reliable as paper records and handwritten signatures. The regulation 'applies to records in electronic form that are created,

modified, archived, retrieved or transmitted under any records requirements' (1) as set forth by a predicate rule. Predicate rules include any requirements set forth by any FDA regulation, such as good laboratory practice (GLP), good manufacturing practice (GMP) and good clinical practice (GCP).

In the years following the introduction of Part 11, as industry began to attempt to comply with its requirements, the implications and broad scope of the rule became apparent. Pharma companies were expected to be making progress towards compliance with Part 11 by:
Assessing their current systems against the requirements
Determining the actions needed for each system to attain compliance
Developing procedural and technical controls
Generating and executing validation and implementation plans


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Lynda Bruce, Principal Engineer in the Life Sciences Business Unit and Annie Broadhurst, Technical Scholar at Cambridge Consultants Ltd

Dr Lynda Bruce is a Principal Engineer in the Life Sciences Business Unit at Cambridge Consultants Ltd where she specialises in regulatory issues affecting process and product development. Lynda joined CCL from Integral Inc, a management consulting firm, where she focused on organisational and strategy issues for clients in the pharmaceutical industry. She has also worked for Wardrop Engineering as a Process Engineer and for Hemosol Inc as a Process Development Engineer.

Annie Broadhurst is a Technical Scholar at Cambridge Consultants Ltd. She also studies Pharmacology at the University of Manchester.

spacer
Dr Lynda Bruce
spacer
spacer
spacer
Annie Broadhurst
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement